FDA Grants Priority Review and accepts BLA for Sacituzumab Govitecan for the Treatment of...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jul 18, 2018 at 9:42 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,741
    Likes Received:
    3
    via
    • PDUFA target date is 1/18/19
    • Sacituzumab govitecan is an antibody drug conjugate (ADC)
    • If appproved it would be the first ADC approved for mTNBC
    • Company has another ADC in Ph II for metastatic colorectal cancer

    article source